Clinical Trials Logo

Refractory T-Cell Lymphoma clinical trials

View clinical trials related to Refractory T-Cell Lymphoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04251065 Active, not recruiting - Clinical trials for Relapsed T-Cell Lymphoma

Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH

Start date: September 3, 2020
Phase: Phase 2
Study type: Interventional

FIL_Dara-GDP is a phase II, open label, multicenter clinical trial. The sponsor of this clinical trial is Fondazione Italiana Linfomi (FIL). The primary objective is to evaluate the efficacy of 4 courses of D-GDP (Daratumumab in combination with Gemcitabine, Cisplatin, Dexamethasone) in terms of complete response in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL) and other nodal lymphomas of T follicular helper cells (TFH cells) origin refractory/relapsed after at least one and no more than two previous lines of therapy.